Format

Send to

Choose Destination
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):16-20. doi: 10.1016/j.pnpbp.2011.12.001. Epub 2011 Dec 9.

CB₂: therapeutic target-in-waiting.

Author information

1
Section on Synaptic Pharmacology, Laboratory for Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20852, USA. atwoodbk@mail.nih.gov

Abstract

CB₂ cannabinoid receptor agonists hold promise as a new class of therapeutics for indications as diverse as pain, neuroinflammation, immune suppression and osteoporosis. These potential indications are supported by strong preliminary data from multiple investigators using diverse preclinical models. However, clinical trials for CB₂ agonists, when they have been reported have generally been disappointing. This review considers possible explanations for the mismatch between promising preclinical data and disappointing clinical data. We propose that a more careful consideration of CB₂ receptor pharmacology may help move CB₂ agonists from "promising" to "effective" therapeutics.

PMID:
22197668
PMCID:
PMC3345167
DOI:
10.1016/j.pnpbp.2011.12.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center